Received May 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (ADACEL) | SANOFI PASTEUR | UNK | — | OT |
pulled out a "tdap" in error thinking she pulled a "vasopressin," mixed it with normal saline and infused it over four hours with no reported adverse event; pulled out a "tdap" in error thinking she pulled a "vasopressin," mixed it with normal saline and infused it over four hours with no reported adverse event; pulled out a "tdap" in error thinking she pulled a "vasopressin," mixed it with normal saline and infused it over four hours with no reported adverse event; Initial information received on 24-Apr-2026 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a patient of unknown age and gender and it was reported pharmacist pulled out a DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (ADACEL) in error thinking she pulled a "vasopressin," mixed it with normal saline and infused it over four hours with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s), family history were not provided. On 24-Apr-2026, the patient received an unknown dose of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE suspension for injection (batch/expiry: unknown) (strength: unknown) as pharmacist pulled out a tdap in error thinking she pulled a "vasopressin", mixed it with normal saline and infused it over four hours via intravenous route in an unknown administration site for immunization with no reported adverse event (wrong product administered) (product preparation error) (incorrect route of product administration) (latency: same day). Action taken: Not applicable. This suspected adverse reaction report was submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error was in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE